In two months, Covid-19 can easily export curbs: Adar Poonawalla

The export restrictions for Covid vaccines are expected to be alleviated within a two-month period by Adar Poonawalla, Chief Executive Officer of the Serum Institute of India (SII), provided India has created a enough stock to cope with the third wave.

The provision of raw materials for Novavax vaccines has improved compared to March and in December, Poonawalla told the media, SII plans to announce its monthly manufacturing plan.

“No export ban was in place, but temporary restrictions were in place and rightly so. In the next month or two I think these will be slowly easy, but I don’t want to go astray. But soon,” he said, adding that India is close to a point in which more than enough stocks of vaccines exist.

The government of India, Poonawalla says, is relieving the export restrictions, and it will follow what the Center thinks is appropriate.

“The Centre has to balance the needs of the country and stockpile vaccines for India in case of the third and fourth waves. Taking lessons from the first and second waves, the government is rightly being very cautious,” he said.

SII is expanding its Covishield capacity, which now stands at around 160 million doses a month. From October, it is expected to touch 200 million doses a month.

On the other hand, the production of the Novavax vaccine is not constrained by SII’s capacities, but by raw materials, Poonawalla said. SII is working on developing alternative vendor sources for critical raw materials. “Developing new supplies takes time. The silver lining is we have got people who can make quality raw materials, but they are inundated with orders from different vaccine companies – from Korea, China, Europe, etc,” he added.

SII is trying its best to scale up the production of the Novavax vaccine, Poonawalla said, and that there have been major improvements in raw material supplies since March. “We will wait and see, and in December, for sure, we can comment on what our monthly production will be,” he said.

As for the Novavax vaccine’s clinical trials on paediatric population, Poonawalla said the company has started trials, and three to four months is the minimum timeframe for that. By January-February, there is a possibility that Covovax (SII-manufactured Novavax vaccine) could be ready for approval for use in kids.

 

Medically Speaking

Recent Posts

Dysautonomia: The Silent Illness Affecting Millions Globally

Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…

2 days ago

Chyawanprash: Your Ayurvedic Shield Against Cough & Cold

https://youtu.be/mdl3AFFFcuk?si=i2cYzTX7WJ-z6wRp Does Chyawanprash Help in Cough & Cold? Exploring Its Benefits and Efficacy Chyawanprash, a…

2 days ago

Why Winter Morning Walks (7-9 AM) Are Perfect for Your Health

Walk In Winter: In winter, the time from 7:00 AM to 9:00 AM is considered…

2 days ago

Does Maida Stick to Your Gut? Debunking Myths and Health Risks

Does Maida Stick To Your Gut Lining: In this article, we debunk the common myth…

2 days ago

Think Twice Before Heating Packaged Milk: Hidden Risks You Should Know!

https://youtu.be/4NTKSfNf1TM?si=Y4xkEOKDUvqpIEZt The Disadvantages of Heating Packaged Milk Milk is a staple in many households and…

2 days ago

MENTAL HEALTH STRUGGLES: THE LONG-TERN IMPACT ON TEENAGERS

A recent study has revealed a growing mental health crisis among teenagers globally, with nearly…

3 days ago